Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861029 · ClinicalTrials.gov registry record · Phase 1
VEG111485: A QTc Study of Pazopanib
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00861029: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT00861029 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00861029, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in subjects with solid tumors. Moxifloxacin, will serve as a positive control.
Interventions
- DRUG Moxifloxacin
- DRUG Pazopanib
- OTHER Placebo for pazopanib
- OTHER Placebo for moxifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-03-19 |
| Est. Completion | 2010-02-15 |
| Phase | Phase 1 |
What the finished NCT00861029 record still lists
NCT00861029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT00861029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00861029 about?
NCT00861029 is a clinical study titled "VEG111485: A QTc Study of Pazopanib". This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in subjects with solid tumors. Moxifloxacin, will serve as a positive control.
What is the current status of trial NCT00861029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2009-03-19. Estimated completion is 2010-02-15.
What interventions are being tested in trial NCT00861029?
The interventions under investigation include: Moxifloxacin (DRUG), Pazopanib (DRUG), Placebo for pazopanib (OTHER), Placebo for moxifloxacin (OTHER).
Who is sponsoring clinical trial NCT00861029?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00861029's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI